Cargando…

2489. Adverse Events with Biktarvy: Post-Marketing Study

BACKGROUND: Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was FDA approved in February 2018. There are no published post-marketing data evaluating safety and efficacy. After large uptake of BIC/FTC/TAF at our institution, reports of rash prompted a real-world review. The purpose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayes, Edwin, Derrick, Caroline, Smalls, Danielle, Smith, Hilary, Kremer, Nicole, Weissman, Sharon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810394/ http://dx.doi.org/10.1093/ofid/ofz360.2167

Ejemplares similares

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
por: Hayes, Edwin, et al.
Publicado: (2020)

1593. Switch to DOVATO in Patients Suppressed on Biktarvy (The SOUND Study), week 48 interim analysis
por: Slim, Jihad, et al.
Publicado: (2023)

2489 Perceptions of “translation” and the application of research across disciplines at the University of Michigan
por: Gravelin, Misty, et al.
Publicado: (2018)

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
por: Gastaldon, C., et al.
Publicado: (2021)

2489. An Innovative Capacity-Building Approach to Enhance Acute Flaccid Paralysis Surveillance During a Wild Poliovirus Type 1 Outbreak in Malawi, October 2022 - March 2023
por: Dagoe, Edward, et al.
Publicado: (2023)

PB2489: ATAXIA LEADING TO A DIAGNOSIS OF PEDIATRIC CNS-ISOLATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN GRISCELLI SYNDROME TYPE 2
por: Tony, Surekha, et al.
Publicado: (2023)

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance
por: Wakabayashi, Tomohito, et al.
Publicado: (2022)

1041. Tenofovir alafenamide associated weight change in persons living with HIV
por: Crowder, Carlysle E, et al.
Publicado: (2020)

Microbiologic Predictors of Pelvic Osteomyelitis Related to Decubitus Ulcers
por: Sharma, Neha, et al.
Publicado: (2017)

Microbiology of Vertebral Osteomyelitis and Implications on Empiric Therapy
por: Clark, Abbye, et al.
Publicado: (2017)

955. Addressing Gaps and Disparities in HIV testing in the Emergency Department
por: Huggett, Ashley, et al.
Publicado: (2020)

Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases
por: Zhu, Siji, et al.
Publicado: (2023)

Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
por: Soldatos, Theodoros G., et al.
Publicado: (2022)

Evaluating Post-Market Adverse Events of The New Hepatitis C Therapies Using FEARS Data
por: Algarni, Majed A.
Publicado: (2022)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
por: Milgrom, Alexander, et al.
Publicado: (2019)

1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections
por: Smith, Bradley, et al.
Publicado: (2018)

Large-scale mining disease comorbidity relationships from post-market drug adverse events surveillance data
por: Zheng, Chunlei, et al.
Publicado: (2018)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy)
por: Stefanizzi, Pasquale, et al.
Publicado: (2023)

Adverse Events Releated to Antibiotic Use in Patients with Myasthenia Gravis
por: Zeitler, Kristen, et al.
Publicado: (2017)

2776. Post-marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Review of Spontaneous Reports Since Introduction
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2019)

1388. Epidemiology and Treatment Outcomes of Nontuberculous Mycobacterial Infections at a Community Teaching Hospital in the Southeastern United States
por: Vivian Tsai, Y, et al.
Publicado: (2021)

Reporting of adverse events for marketed drugs: Need for strengthening safety database
por: Apte, Aditi Anand
Publicado: (2016)

Cannabis and cannabinoids for mental health indications: evidence of effect and adverse events
por: Bramness, J. G.
Publicado: (2023)

106. META-INSTI: Metabolic Adverse Events Following Integrase Strand Transfer Inhibitor Administration in Spontaneous Adverse Event Reports
por: Murray, Milena M, et al.
Publicado: (2020)

1969. Comparison of Adverse Event Rates Between Patients Treated With Ceftaroline or Ceftriaxone
por: Jansen, Jeffrey W, et al.
Publicado: (2018)

892. Risk Factors for Adverse Events in Children Receiving Outpatient Antibiotic Therapy
por: Gillon, Jessica, et al.
Publicado: (2019)

1127. Utilization of Combination Anti-fungal Therapy in Hospitalized Children and Adverse Events
por: Scardina, Tonya, et al.
Publicado: (2019)

Effects of Nurse Staffing, Work Environment, Education on Adverse Events in Nursing Homes
por: Choi, Seonhwa, et al.
Publicado: (2020)

Potential Antipsychotic Side Effects and Adverse Events of Assisted Living Residents With Dementia
por: Beeber, Anna, et al.
Publicado: (2020)

Older Couples Coping With Adverse Life Events: The Importance of Dyadic Personality Profiles
por: Wang, Shuangshuang, et al.
Publicado: (2020)

A Pharmacovigilance Approach for Post-Marketing in Japan Using the Japanese Adverse Drug Event Report (JADER) Database and Association Analysis
por: Fujiwara, Masakazu, et al.
Publicado: (2016)

Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System
por: Mina, Syeda A., et al.
Publicado: (2021)

Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports
por: Ekhart, Corine, et al.
Publicado: (2022)

Comparison of the post-marketing safety profile between influenza and COVID-19 vaccines: An analysis of the vaccine adverse event reporting system
por: Al-Ahmari, Abdullah K., et al.
Publicado: (2022)

Adverse Events of Vaccination against Hepatitis B Virus in Post-Marketing Surveillance from 2005 to 2017 in Guangdong Province, China
por: Liu, Yu, et al.
Publicado: (2022)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
por: Jiang, Tingting, et al.
Publicado: (2022)

Safety of Sublingual Immunotherapy: A Secondary Analysis of Post-marketing Adverse Events Reports Using a Japanese Public Database
por: Kaneda, Yudai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nbh29hk008qa7uoodoaj33f23l